Author:
Wu Ying,Wang Qin,Zhang Jian,Cao Jun,Wang Biyun,Hu Xichun
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Faneyte IF, Kristel PM, van de Vijver MJ (2004) Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24(5a):2931–2939
2. Chien AJ, Moasser MM (2008) Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol 35(2 Suppl 2):S1–S14 quiz S39
3. Li Q, Yang Z, Fan J, He J, Zhang B, Yang H, Xie X, Tang Z, Li H, Qiao Y, Zhang P (2017) A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients. Oncotarget 8(44):75864–75873
4. Network NCC: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2018. 2018.
5. (2011) Eribulin mesylate (Halaven) for breast cancer. Med Lett Drugs Ther 53(1362):30–31
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献